The Convergence of Science and Hope

Argos Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. The Company has developed a pipeline of products based on its proprietary Arcelis technology platform.

View the Arcelis Platform

hp_adapt_its_personal

Argos in The News

818534817074816150439ec505-52fa-44d9-8887-4400ea8c1936c3112c58-eb52-4515-b778-ed0eefe8cdcdcf9e0033-2d30-4556-952b-62134d6d66aaARGS_News_2015_3_30_General_Releases.pdfARGS_News_2015_3_20_General_Releases.pdfARGS_News_2015_3_16_General_Releases.pdf2735219990172011232015-3-30T16:5:0-4:02015-3-20T8:30:0-4:02015-3-16T16:30:0-4:0904061902658901854General ReleasesGeneral ReleasesGeneral ReleasesDr. Mark DeBenedette Will Review Outcomes From a Phase IIb Clinical Trial of Investigational Immunotherapy for the Treatment of HIVArgos Therapeutics Reports Fourth Quarter and Year-End 2014 Financial ResultsArgos Therapeutics Director of Immunology to Present at HIV Vaccines MeetingArgos Therapeutics to Hold Fourth Quarter and Year-End 2014 Financial Results Conference Call on Monday, March 30, 2015888888201520152015No Error0

Argos Therapeutics Reports Fourth Quarter and Year-End 2014 Financial Results
Read more

Argos Therapeutics Director of Immunology to Present at HIV Vaccines Meeting
Read more

Argos Therapeutics to Hold Fourth Quarter and Year-End 2014 Financial Results Conference Call on Monday, March 30, 2015
Read more

> More News & Events Here.

1999

When Our Company Was Founded

2006

First Arcelis product (AGS-003) clinical trial initiated in mRCC

2013

Phase 3 mRCC ADAPT Study Launched

180

Newly diagnosed RCC patients daily in the US, of which ~ 30 will present with stage IV or metastatic RCC